» Articles » PMID: 10887122

The Autolysis Loop of Activated Protein C Interacts with Factor Va and Differentiates Between the Arg506 and Arg306 Cleavage Sites

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2000 Jul 11
PMID 10887122
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

The anticoagulant human plasma serine protease, activated protein C (APC), inactivates blood coagulation factors Va (FVa) and VIIIa. The so-called autolysis loop of APC (residues 301-316, equivalent to chymotrypsin [CHT] residues 142-153) has been hypothesized to bind FVa. In this study, site-directed mutagenesis was used to probe the role of the charged residues in this loop in interactions between APC and FVa. Residues Arg306 (147 CHT), Glu307, Lys308, Glu309, Lys311, Arg312, and Arg314 were each individually, or in selected combinations, mutated to Ala. The purified recombinant protein C mutants were characterized using activated partial thromboplastin time (APTT) clotting assays and FVa inactivation assays. Mutants 306A, 308A, 311A, 312A, and 314A had mildly reduced anticoagulant activity. Based on FVa inactivation assays and APTT assays using purified Gln506-FVa and plasma containing Gln506-FV, it appeared that these mutants were primarily impaired for cleavage of FVa at Arg506. Studies of the quadruple APC mutant (306A, 311A, 312A, and 314A) suggested that the autolysis loop provides for up to 15-fold discrimination of the Arg506 cleavage site relative to the Arg306 cleavage site. This study shows that the loop on APC of residues 306 to 314 defines an FVa binding site and accounts for much of the difference in cleavage rates at the 2 major cleavage sites in FVa. (Blood. 2000;96:585-593)

Citing Articles

Exploring the Diversity and Function of Serine Proteases in Toxicofera Reptile Venoms: A Comprehensive Overview.

Vidal J, Schwartz M, Garay A, Valadares N, Bueno R, Monteiro A Toxins (Basel). 2024; 16(10).

PMID: 39453204 PMC: 11511063. DOI: 10.3390/toxins16100428.


Selective modulation of activated protein C activities by a nonactive site-targeting nanobody library.

Sim D, Shukla M, Mallari C, Fernandez J, Xu X, Schneider D Blood Adv. 2023; 7(13):3036-3048.

PMID: 36735416 PMC: 10331410. DOI: 10.1182/bloodadvances.2022008740.


Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia.

Zhao X, Wilmen A, Wang D, Wang X, Bauzon M, Kim J Nat Commun. 2020; 11(1):2992.

PMID: 32532974 PMC: 7293249. DOI: 10.1038/s41467-020-16720-9.


C-terminal residues of activated protein C light chain contribute to its anticoagulant and cytoprotective activities.

Yamashita A, Zhang Y, Sanner M, Griffin J, Mosnier L J Thromb Haemost. 2020; 18(5):1027-1038.

PMID: 32017367 PMC: 7380734. DOI: 10.1111/jth.14756.


Activation-resistant homozygous protein C R229W mutation causing familial perinatal intracranial hemorrhage and delayed onset of thrombosis.

Alsultan A, Gale A, Kurban K, Khalifah M, Albadr F, Griffin J Thromb Res. 2016; 143:17-21.

PMID: 27172833 PMC: 4943460. DOI: 10.1016/j.thromres.2016.04.011.